Korva is a scroll of the internet’s best ideas.
Trial that scared women off estrogen
The trial and its fallout
The hypothesis looked perfect. Menopause means the body stops making estrogen, so replace the estrogen. Then the results came back with more breast cancer, more clots in the legs, and more strokes, and the trial was shut down instead of recalibrated for women of different ages or different forms of treatment.
The whole concept of hormone replacement left women panicked and doctors unwilling to discuss it. Scientists doubted the conclusion, and the question was reopened with different agents, different patient populations, and different forms: a vaginal insert, a patch, or a pill. It is now called menopause hormone treatment, because replacement is not what every woman needs.
What treatment is for
Hormone treatment is not recommended for primary prevention, so no one starts it to protect the heart or brain. It has never been shown to work for that, and the clot and stroke risks apply to certain populations. For women with symptoms such as hot flashes, sleep disorders, or sexual dysfunction, the decision comes down to a risk and benefit conversation.
A training gap
Few medical students get training in menopause hormone treatment, and those long conversations take time, so many women met doctors who would not discuss it. Menopause centers are now opening, and OBGYNs, internists, and cardiologists are training in menopause medicine.
Why was the hormone trial stopped early?
The Women's Health Initiative tested estrogen plus progestin in over 16,000 postmenopausal women. In July 2002, after an average of about five years of follow-up, its monitoring board stopped that arm because the risk of invasive breast cancer had crossed the safety boundary set in advance. Heart disease, stroke, and blood clots were also more common in the treated group. The results were published in JAMA that month.
Why did participants' ages matter so much?
The women in the trial averaged about 63 years old, and many were more than a decade past menopause. Later analyses of the data found a different pattern among women who began treatment closer to menopause. This led researchers to propose the timing hypothesis, which holds that the effect of estrogen on blood vessels depends on how healthy they are when it starts. Trials built to test that idea, such as KEEPS and ELITE, enrolled women near the start of menopause.
How does a patch differ from a pill?
Estrogen swallowed as a pill passes through the liver before it reaches the rest of the body. That first pass changes the production of clotting proteins. Estrogen absorbed through the skin enters the bloodstream directly and skips that step. Observational studies have found lower clot risk with skin patches than with oral estrogen.
More from Next Question with Katie Couric
